Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic tranexamic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with control (moderate certainty).
1 finding from 1 review
Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
Secondary hemorrhage at any time point · people with traumatic hyphema
Systemic tranexamic acid may leads to lower secondary hemorrhage at any time point compared with control (low certainty).
1 finding from 1 review
Nausea · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Presence of dry socket · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
Tranexamic acid (AMCA cones) showed no clear difference in presence of dry socket compared with placebo (lactose cones); GRADE not reported.
1 finding from 1 review
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
Risk of receiving any allogeneic blood product (data only available for intraoperative blood product use) · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Tranexamic acid changes risk of receiving any allogeneic blood product (data only available… compared with placebo (very low certainty).
1 finding from 1 review
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).
1 finding from 1 review
Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery
Summary of findings: Tranexamic acid showed no clear difference in risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with placebo (low certainty).
1 finding from 1 review